Skip to main content
. 2016 Nov 29;8(2):3144–3155. doi: 10.18632/oncotarget.13673

Figure 1. Expression patterns of RNF2 and SIK1 in human HCC.

Figure 1

A. Relationship between RNF2 amplification and HCC prognosis. Kaplan-Meier curves based on data from TCGA show that RNF2 amplification in HCC was associated with shorter overall survival (P < 0.05). B. RNF2 and SIK1 expression in HCC tissues and paired normal liver tissues. Western blots of RNF2 and SIK1 in six representative paired samples of non-tumor tissue (N) and HCC tissue (T) are shown. β-Actin was used as a control for protein load. C. Expression patterns of RNF2 and SIK1 immunoreactivity in HCC samples and in non-tumor tissues from a representative case. D. RNF2 expression levels in noncancerous liver tissues were lower than those in HCC tissues (left) (P < 0.05). Conversely, SIK1 expression levels in noncancerous liver tissues were higher than those in HCC tissues (right) (P < 0.05). E. Low SIK1 levels were correlated with high RNF2 expression in HCC (P < 0.05). The median expression levels of SIK1 and RNF2 were used as the cutoff values. F. Kaplan-Meier curves show that HCC patients with high RNF2 and low SIK1 immunoreactivity had a poorer prognosis than patients with low RNF2 and high SIK1 immunoreactivity did. The data are expressed as the mean ± SD. The results are representative of three independent experiments. *P < 0.05, **P < 0.01.